CONRAD HERBERT J 4

What Happened

• Herbert J. Conrad, a director of Celldex Therapeutics (CLDX), was granted a derivative award of 26,000 shares on 2026-06-25. The reported acquisition price is $0.00, indicating an option/award rather than an open-market purchase or sale. The grant is reported as a derivative instrument (not an immediate sale or purchase of common stock).

Key Details

• Transaction date: 2026-06-25; filing date: 2026-06-29 (filed within the standard two business days).
• Transaction type: Award/Grant (derivative) — 26,000 shares at $0.00.
• Footnote: F1 — the grant represents an option issued under Celldex’s 2021 Omnibus Equity Incentive Plan.
• Shares owned after the transaction: Not specified in the provided filing.
• No sale or immediate exercise reported; this is a grant of rights to acquire shares in the future.

Context

• This filing reports an option/award grant, which gives the director the right to acquire shares later under plan terms (vesting/exercise conditions not shown). Such grants are typically part of director compensation and do not reflect an immediate purchase or sale of stock. The Form 4 was filed timely.